Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study
Titel:
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study
Auteur:
Randrian, Violaine Adenis, Antoine Desrame, Jérôme Barbier, Emilie Di Fiore, Frédéric Lièvre, Astrid Dahan, Laetitia Laurent-Puig, Pierre Mineur, Laurent Breysacher, Gilles Roquin, Guillaume Louafi, Samy Lopez, Anthony Louvet, Christophe Borg, Christophe Metges, Jean Philippe Faroux, Roger Gaba, Lila Manfredi, Sylvain Tougeron, David